Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NW13
UPID:
RBM28_HUMAN
Alternative names:
RNA-binding motif protein 28
Alternative UPACC:
Q9NW13; A4D100; B4DU52; E9PDD9; Q53H65; Q96CV3
Background:
RNA-binding protein 28, alternatively known as RNA-binding motif protein 28, plays a crucial role as a nucleolar component of the spliceosomal ribonucleoprotein complexes. This protein is pivotal in the processing of pre-mRNA, indicating its essential function in cellular RNA metabolism.
Therapeutic significance:
RNA-binding protein 28 is linked to Alopecia, neurologic defects, and endocrinopathy syndrome, characterized by hair loss, intellectual disability, and endocrine issues. Understanding the role of RNA-binding protein 28 could open doors to potential therapeutic strategies for this multifaceted syndrome.